- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02545478
Biomarkers in Infection
Early Detection of Inflammatory Biomarkers in Infection
Aperçu de l'étude
Statut
Les conditions
Description détaillée
The body's immune system and a subsequent inflammatory response are triggered during infection. The detection of an activated immune system, and an indication of the degree of the host response, is helpful to the clinician both in assessing the severity of infection and in patient treatment and management. Currently, the white blood cell count and the differential are the most common laboratory parameters for measuring host response. The sedimentation rate and CRP are also used to detect inflammation. However, these tests are all imperfect predictors, and a test providing a better assessment of immune response would be helpful to the clinician in patient care. Additionally, understanding host response to infection may be helpful in understanding the biology and pathophysiology of sepsis. There are other biomarkers and inflammatory markers that may be found early in the initial presentation of infection such as cytokines (VEGF IL-1,IL-4,IL-6, IL-10, PAF, TNF, lectins iNoS,etc.) and clotting factors (protein C, d-dimer, complements involved in the clotting cascade, CRP, etc) that may provide a means of early detection of systemic inflammation, cell dysfunction, and related conditions. Early identification of patients at risk for systemic inflammatory syndromes, sepsis and septic shock may help direct patients to earlier antibiotic administration and early intervention with goal directed therapy. It may also serve as a tool for risk stratification when components such as age, comorbid illness and infection type are included.
The endothelium and endothelial cell markers are important in sepsis, yet a somewhat under-studied field of research. Additionally, the endothelium is a key regulator of the microcirculation, a place where oxygen diffusion occurs. One focus of this study is to measure endothelial markers (ie VEGF) and other cytokines with the goal of correlating these markers with severity of sepsis. Another focus is to study the response of various components in the blood, including the leukocytes, red cells, the endothelium, as well as cellular components such as the mitochondria. We will specifically look at alterations in thiamine, Vitamin D, CoQ10,l-carnitine and other nutrients as part of (and as related to) the body's response. Recently, a non-invasive method of assessing microvascular circulation by orthogonal polarization spectral (OPS) imagery has become available using a non-invasive technology known as orthogonal polarization spectroscopy. This technique enables direct visualization and quantification of microcirculatory blood flow, and represents an important surrogate outcome to which endothelial cell marker may be correlated. This will involve placing the microscopy probe gently against the sublingual mucosa and collecting a videotape of the circulation lasting about twenty seconds. This process involves minimal (or no) risk - it is akin to taking a temperature and uses no radiation. This videotape will be examined later by a novel software program that quantifies the circulation and used as an important surrogate outcome measure. Additionally, we are going to perform echocardiography to better understand the heart's response to sepsis, and correlated the molecular responses that we find with the changes in the responses by the heart.
This is a multicenter, observational pilot study which aims to evaluate how early biomarkers of infection an inflammation perform in identifying patients at risk for poor outcomes in sepsis and septic shock. The study will utilize a cohort of patients presenting to the ED with suspected infection as well as non-infected control population.
These patients will be compared with a non-infected population.
Enrolled subjects in the infected group will have blood samples and chart review obtained at enrollment, 24, 48 and 72 hours. For the control group, only a single blood draw will be collected at enrollment.
Enrolled subjects will also undergo physiologic assessments using echocardiography, Microscan, Non-invasive cardiac output monitor (NICOM), extremity temperature as well as End-Tidal C02 measurements if a trained researcher is present.
Type d'étude
Inscription (Anticipé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Nathan Shapiro, MD MPH
- Numéro de téléphone: 617-754-2343
- E-mail: nshapiro@bidmc.harvard.edu
Sauvegarde des contacts de l'étude
- Nom: Sharon R Hayes, RN
- Numéro de téléphone: 617-754-2334
- E-mail: srhayes@bidmc.harvard.edu
Lieux d'étude
-
-
-
Aarhus, Danemark
- Pas encore de recrutement
- Aarhus Universitetshospital
-
Contact:
- Hans Kirkegaard
- E-mail: Hans Kirkegaard <hanskirkegaard@dadlnet.dk>
-
Chercheur principal:
- Hans Kirkegaard, MD
-
-
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02215
- Recrutement
- Beth Israel Deaconess Medical Center
-
Contact:
- Nathan Shapiro, MD MPH
- Numéro de téléphone: 617-754-2343
- E-mail: nshapiro@bidmc.harvard.edu
-
Boston, Massachusetts, États-Unis, 02114
- Actif, ne recrute pas
- Massachusetts General Hospital
-
Boston, Massachusetts, États-Unis, 02215
- Actif, ne recrute pas
- Brigham and Women's Hospital
-
Worcester, Massachusetts, États-Unis, 01608
- Recrutement
- St. Vincent's Hospital
-
Contact:
- David Miru, RN
- Numéro de téléphone: 508-363-5286
- E-mail: dmiru@bidmc.harvard.edu
-
Contact:
- Pamel Sigel, RN
- Numéro de téléphone: 508-363-7018
- E-mail: PAMELA.SIGEL@stvincenthospital.com
-
Chercheur principal:
- Nathan Shapiro, MD MPH
-
-
New York
-
Brooklyn, New York, États-Unis, 11215
- Recrutement
- New York Methodist Hospital
-
Contact:
- Robert Birkhahn, MD
-
Chercheur principal:
- Rorber Birkhahn, MD
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37232
- Recrutement
- Vanderbiltt University
-
Contact:
- Wesley Self, MD
- Numéro de téléphone: 615-936-0253
- E-mail: wesley.self@vanderbilt.edu
-
Chercheur principal:
- Wesley Self, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria for Infected subjects:
- Age 18 years of age or older
- Confirmed or suspected infection
Inclusion Criteria for Control Subjects:
- Age 18 years of age or older
- A non-infectious clinical presentation to include
- Normal white blood cell count ( > 4,000 and/or < 12,000)
- Normothermia ( > 96.5 and/or less 100.4)
- Absence of the following clinical complaints: productive cough, fever, pyuria, rash
- No evidence of acute coronary syndrome
Exclusion Criteria for Control Subjects:
- Suspected infection
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
---|
Infected Group
subjects with suspected infection
|
Non-infected group
subjects without any infection
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
28 day in-hospital mortality
Délai: within 28 days after inclusion
|
participants will be followed up for 28 days
|
within 28 days after inclusion
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Organ Dysfunction assessed by Sepsis-related Organ Failure Assessment (SOFA) Score
Délai: within 24 hours
|
within 24 hours
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Nathan Shapiro, MD MPH, Beth Israel Deaconess Medical Center
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2005P000116
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .